Cadrenal Therapeutics to attend Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 By Investing.com
PONTE VEDRA, Fla.–(BUSINESS WIRE)–Cadrenal Therapeutics, Inc.(Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in an online fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, which will be held virtually on Monday, January 13, 2025.
Cadrenal Therapeutics is a biopharmaceutical company focused on the development of tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
A fireside chat will be held at 10:30 a.m. ET on Monday, January 13, 2025. The webcast can be accessed by visiting the conference homepage at https://lythampartners.com/health2025/ or directly at https:// lythampartners. com/health2025/cvkd. A replay of the fireside chat will also be available via the same links.
1×1 investor meetings will be available after the event upon request by contacting your Lytham representative at 1×1@lythampartners.com.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company in advanced clinical development focused on the development of tecarfarin, a novel oral and reversible anticoagulant for the prevention of heart attack, stroke and death caused by blood clots in patients with rare cardiovascular conditions.
Tecarfarin is a vitamin K antagonist (VKA) that potentially represents the first new therapeutic innovation in VKA anticoagulation in 70 years. Tecarfarin is designed to be a superior and safer chronic oral anticoagulant therapy compared to warfarin for patients with implanted cardiac devices or rare cardiovascular conditions.
Cadrenal Therapeutics’ drug candidate, tecarfarin, is expected to enter its pivotal Phase 3 trial during 2025. The company’s clinical program for tecarfarin is supported by extensive data showing the molecule’s potential as an alternative to warfarin, with safety data indicating fewer side effects such as brain stroke, heart attack, bleeding, and death compared with warfarin. The FDA granted tecarfarin orphan drug (ODD) designation for heart failure patients with implanted left ventricular assist devices (LVADs), as well as ODD and Fast Track designation for end-stage renal disease (ESKD) patients with atrial fibrillation (AFib).
For more information, visit www.cadrenal.com and connect with the company at LinkedIn.
See the original version on businesswire.com: https://www.businesswire.com/news/home/20250109166162/en/
Corporate and investor relations
Lisa DeScenza
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com
The media
Andrija Korda
LaVoieHealthScience
(617) 865-0043
akorda@lavoiehealthscience.com
Source: Cadrenal Therapeutics, Inc.
